This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

A new animal-based study has found GLP-1s could have the potential to do more than curb appetite—they may even extend life ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It's administered with a tiny needle that punctures ...

An experimental study of individuals with moderate to severe alcohol use disorder found that semaglutide did not reduce a ...

Older female mice—equivalent in age to 60-year-old women—given daily injections of the active ingredient in Ozempic lived ...

MISSISSAUGA, ON, Dec. 15, 2025 /CNW/ - Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with Conditions (NOC/c)] for Wegovy® ...

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties from compounding the drug. Our FDA/Food, Drug & Device and ...

Chances are you already have it in your home.

A new diabetes pill beat oral semaglutide on blood sugar and weight loss, but nearly 10% stopped treatment due to side ...

MISSISSAUGA, ON, March 2, 2026 /CNW/ - Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV ...